Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma

Volume: 17, Issue: 4, Pages: 238 - 251
Published: Jan 3, 2020
Abstract
Hepatocellular carcinoma (HCC) is the most common form of primary adult liver cancer. After nearly a decade with sorafenib as the only approved treatment, multiple new agents have demonstrated efficacy in clinical trials, including the targeted therapies regorafenib, lenvatinib and cabozantinib, the anti-angiogenic antibody ramucirumab, and the immune checkpoint inhibitors nivolumab and pembrolizumab. Although these agents offer new promise to...
Paper Details
Title
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Published Date
Jan 3, 2020
Volume
17
Issue
4
Pages
238 - 251
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.